Targeted pharmacotherapy after somatic cancer mutation screening.
Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+KITscreening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+KITscreening were required for targeted drug selection, with the remaining 52% (22/42) prescribed drugs independent of the screening results for various reasons. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.
Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Adelaide, Australia.
Thomas M
TM
Polasek
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
Karen
K
Ambler
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
Hamish S
HS
Scott
Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Adelaide, Australia.
Michael J
MJ
Sorich
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
Peter A
PA
Kaub
Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Adelaide, Australia.
Andrew
A
Rowland
School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
Michael D
MD
Wiese
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Adelaide, Australia.
Ganessan
G
Kichenadasse
: targeted pharmacotherapy; bevacizumab; dabrafenib erlotinib; malignant melanoma; metastatic colorectal cancer; non-small cell lung cancer; oncology; precision medicine